Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
Aim Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature mir...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2013-09, Vol.43 (9), p.942-949 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 949 |
|---|---|
| container_issue | 9 |
| container_start_page | 942 |
| container_title | Hepatology research |
| container_volume | 43 |
| creator | Seko, Yuya Ikeda, Kenji Kawamura, Yusuke Fukushima, Taito Hara, Tasuku Sezaki, Hitomi Hosaka, Tetsuya Akuta, Norio Suzuki, Fumitaka Kobayashi, Masahiro Suzuki, Yoshiyuki Saitoh, Satoshi Arase, Yasuji Kumada, Hiromitsu |
| description | Aim
Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature miriplatin is unclear.
Methods
Chemotherapy efficacy was evaluated by dynamic computed tomography 1–3 months after TACE, according to the Modified Response Evaluation Criteria in Solid Tumors. A total of 203 patients with HCC who received TACE with miriplatin for the first time were included in a follow‐up study to retrospectively investigate its efficacy and safety. Overall, 45 patients underwent TACE with warmed (40°C) miriplatin and 158 patients received TACE with room temperature miriplatin.
Results
Seventy patients (44.3%) treated with room temperature miriplatin and 32 patients (71.1%) who received warmed miriplatin experienced complete or partial responses. Multivariate analysis identified miriplatin temperature (warmed miriplatin, risk ratio (RR) = 2.26, P = 0.047), tumor number (solitary, RR = 3.48, P = 0.007), α‐fetoprotein (AFP) level ( |
| doi_str_mv | 10.1111/hepr.12041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1433271193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1433271193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3911-4d2ba19c09b01bd964ab08a6a685a846d415aa007aa89d5e7661d2b5ba9917c3</originalsourceid><addsrcrecordid>eNp9kFtr3DAQhUVpaG596Q8oeiwBJxpLluzHdMmlIbSlLKRvYizLrFrb2kgy2-2vj7ab5LFCaMTwncPMIeQDsHPI52Jl1-EcSibgDTmCWpUF4-Ln2_zntSwkF_KQHMf4izFQrBTvyGHJOYO6giPyeDkll-bRB2r73hk0W-p7mgJO0WBa2WQDxZBfhwM1Kzt6O7Z-cH8xOT_RjUsrusEw2o6OLrj1kPsTzTdPhckbOwzzgIEaDMZNfsRTctDjEO3753pCltdXy8Vtcf_t5svi8r4wvAEoRFe2CI1hTcug7RopsGU1SpR1hbWQnYAKkTGFWDddZZWUkCVVi00DyvAT8mlvuw7-cbYx6dHF3TQ4WT9HDYLzUgE0PKNne9QEH2OwvV4HN2LYamB6l7DeJaz_JZzhj8--c5uXfkVfIs0A7IGNG-z2P1b69ur7jxfTYq9xMdk_rxoMv7VUXFX64euNXn5WC3V3x_U1fwI7g5gW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1433271193</pqid></control><display><type>article</type><title>Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Seko, Yuya ; Ikeda, Kenji ; Kawamura, Yusuke ; Fukushima, Taito ; Hara, Tasuku ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Akuta, Norio ; Suzuki, Fumitaka ; Kobayashi, Masahiro ; Suzuki, Yoshiyuki ; Saitoh, Satoshi ; Arase, Yasuji ; Kumada, Hiromitsu</creator><creatorcontrib>Seko, Yuya ; Ikeda, Kenji ; Kawamura, Yusuke ; Fukushima, Taito ; Hara, Tasuku ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Akuta, Norio ; Suzuki, Fumitaka ; Kobayashi, Masahiro ; Suzuki, Yoshiyuki ; Saitoh, Satoshi ; Arase, Yasuji ; Kumada, Hiromitsu</creatorcontrib><description>Aim
Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature miriplatin is unclear.
Methods
Chemotherapy efficacy was evaluated by dynamic computed tomography 1–3 months after TACE, according to the Modified Response Evaluation Criteria in Solid Tumors. A total of 203 patients with HCC who received TACE with miriplatin for the first time were included in a follow‐up study to retrospectively investigate its efficacy and safety. Overall, 45 patients underwent TACE with warmed (40°C) miriplatin and 158 patients received TACE with room temperature miriplatin.
Results
Seventy patients (44.3%) treated with room temperature miriplatin and 32 patients (71.1%) who received warmed miriplatin experienced complete or partial responses. Multivariate analysis identified miriplatin temperature (warmed miriplatin, risk ratio (RR) = 2.26, P = 0.047), tumor number (solitary, RR = 3.48, P = 0.007), α‐fetoprotein (AFP) level (<50 ng/mL, RR = 2.35, P = 0.012) and history of TACE (no history, RR = 2.22, P = 0.041) as predictors of objective response following TACE with miriplatin, and no serious complications were observed.
Conclusion
Warm temperature, solitary tumors, low AFP level and first TACE are significant and independent predictors of objective response after TACE using miriplatin. These results suggest that warmed miriplatin can be considered as one of the standard treatments for unresectable HCC.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.12041</identifier><identifier>PMID: 23301851</identifier><language>eng</language><publisher>Netherlands: Blackwell Publishing Ltd</publisher><subject>hepatocellular carcinoma ; miriplatin ; transcatheter arterial chemoembolization</subject><ispartof>Hepatology research, 2013-09, Vol.43 (9), p.942-949</ispartof><rights>2012 The Japan Society of Hepatology</rights><rights>2012 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3911-4d2ba19c09b01bd964ab08a6a685a846d415aa007aa89d5e7661d2b5ba9917c3</citedby><cites>FETCH-LOGICAL-c3911-4d2ba19c09b01bd964ab08a6a685a846d415aa007aa89d5e7661d2b5ba9917c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.12041$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.12041$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23301851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seko, Yuya</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Fukushima, Taito</creatorcontrib><creatorcontrib>Hara, Tasuku</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Saitoh, Satoshi</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><title>Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature miriplatin is unclear.
Methods
Chemotherapy efficacy was evaluated by dynamic computed tomography 1–3 months after TACE, according to the Modified Response Evaluation Criteria in Solid Tumors. A total of 203 patients with HCC who received TACE with miriplatin for the first time were included in a follow‐up study to retrospectively investigate its efficacy and safety. Overall, 45 patients underwent TACE with warmed (40°C) miriplatin and 158 patients received TACE with room temperature miriplatin.
Results
Seventy patients (44.3%) treated with room temperature miriplatin and 32 patients (71.1%) who received warmed miriplatin experienced complete or partial responses. Multivariate analysis identified miriplatin temperature (warmed miriplatin, risk ratio (RR) = 2.26, P = 0.047), tumor number (solitary, RR = 3.48, P = 0.007), α‐fetoprotein (AFP) level (<50 ng/mL, RR = 2.35, P = 0.012) and history of TACE (no history, RR = 2.22, P = 0.041) as predictors of objective response following TACE with miriplatin, and no serious complications were observed.
Conclusion
Warm temperature, solitary tumors, low AFP level and first TACE are significant and independent predictors of objective response after TACE using miriplatin. These results suggest that warmed miriplatin can be considered as one of the standard treatments for unresectable HCC.</description><subject>hepatocellular carcinoma</subject><subject>miriplatin</subject><subject>transcatheter arterial chemoembolization</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kFtr3DAQhUVpaG596Q8oeiwBJxpLluzHdMmlIbSlLKRvYizLrFrb2kgy2-2vj7ab5LFCaMTwncPMIeQDsHPI52Jl1-EcSibgDTmCWpUF4-Ln2_zntSwkF_KQHMf4izFQrBTvyGHJOYO6giPyeDkll-bRB2r73hk0W-p7mgJO0WBa2WQDxZBfhwM1Kzt6O7Z-cH8xOT_RjUsrusEw2o6OLrj1kPsTzTdPhckbOwzzgIEaDMZNfsRTctDjEO3753pCltdXy8Vtcf_t5svi8r4wvAEoRFe2CI1hTcug7RopsGU1SpR1hbWQnYAKkTGFWDddZZWUkCVVi00DyvAT8mlvuw7-cbYx6dHF3TQ4WT9HDYLzUgE0PKNne9QEH2OwvV4HN2LYamB6l7DeJaz_JZzhj8--c5uXfkVfIs0A7IGNG-z2P1b69ur7jxfTYq9xMdk_rxoMv7VUXFX64euNXn5WC3V3x_U1fwI7g5gW</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Seko, Yuya</creator><creator>Ikeda, Kenji</creator><creator>Kawamura, Yusuke</creator><creator>Fukushima, Taito</creator><creator>Hara, Tasuku</creator><creator>Sezaki, Hitomi</creator><creator>Hosaka, Tetsuya</creator><creator>Akuta, Norio</creator><creator>Suzuki, Fumitaka</creator><creator>Kobayashi, Masahiro</creator><creator>Suzuki, Yoshiyuki</creator><creator>Saitoh, Satoshi</creator><creator>Arase, Yasuji</creator><creator>Kumada, Hiromitsu</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma</title><author>Seko, Yuya ; Ikeda, Kenji ; Kawamura, Yusuke ; Fukushima, Taito ; Hara, Tasuku ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Akuta, Norio ; Suzuki, Fumitaka ; Kobayashi, Masahiro ; Suzuki, Yoshiyuki ; Saitoh, Satoshi ; Arase, Yasuji ; Kumada, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3911-4d2ba19c09b01bd964ab08a6a685a846d415aa007aa89d5e7661d2b5ba9917c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>hepatocellular carcinoma</topic><topic>miriplatin</topic><topic>transcatheter arterial chemoembolization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seko, Yuya</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Fukushima, Taito</creatorcontrib><creatorcontrib>Hara, Tasuku</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Saitoh, Satoshi</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><collection>Istex</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seko, Yuya</au><au>Ikeda, Kenji</au><au>Kawamura, Yusuke</au><au>Fukushima, Taito</au><au>Hara, Tasuku</au><au>Sezaki, Hitomi</au><au>Hosaka, Tetsuya</au><au>Akuta, Norio</au><au>Suzuki, Fumitaka</au><au>Kobayashi, Masahiro</au><au>Suzuki, Yoshiyuki</au><au>Saitoh, Satoshi</au><au>Arase, Yasuji</au><au>Kumada, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2013-09</date><risdate>2013</risdate><volume>43</volume><issue>9</issue><spage>942</spage><epage>949</epage><pages>942-949</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
Patients with unresectable hepatocellular carcinoma (HCC) often undergo transcatheter arterial chemoembolization (TACE). Miriplatin is a lipophilic cisplatin derivative used in TACE that is effective in HCC. However, the difference in antitumor efficacy between warmed versus room temperature miriplatin is unclear.
Methods
Chemotherapy efficacy was evaluated by dynamic computed tomography 1–3 months after TACE, according to the Modified Response Evaluation Criteria in Solid Tumors. A total of 203 patients with HCC who received TACE with miriplatin for the first time were included in a follow‐up study to retrospectively investigate its efficacy and safety. Overall, 45 patients underwent TACE with warmed (40°C) miriplatin and 158 patients received TACE with room temperature miriplatin.
Results
Seventy patients (44.3%) treated with room temperature miriplatin and 32 patients (71.1%) who received warmed miriplatin experienced complete or partial responses. Multivariate analysis identified miriplatin temperature (warmed miriplatin, risk ratio (RR) = 2.26, P = 0.047), tumor number (solitary, RR = 3.48, P = 0.007), α‐fetoprotein (AFP) level (<50 ng/mL, RR = 2.35, P = 0.012) and history of TACE (no history, RR = 2.22, P = 0.041) as predictors of objective response following TACE with miriplatin, and no serious complications were observed.
Conclusion
Warm temperature, solitary tumors, low AFP level and first TACE are significant and independent predictors of objective response after TACE using miriplatin. These results suggest that warmed miriplatin can be considered as one of the standard treatments for unresectable HCC.</abstract><cop>Netherlands</cop><pub>Blackwell Publishing Ltd</pub><pmid>23301851</pmid><doi>10.1111/hepr.12041</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2013-09, Vol.43 (9), p.942-949 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1433271193 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | hepatocellular carcinoma miriplatin transcatheter arterial chemoembolization |
| title | Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A57%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20efficacy%20of%20transcatheter%20arterial%20chemoembolization%20with%20warmed%20miriplatin%20in%20hepatocellular%20carcinoma&rft.jtitle=Hepatology%20research&rft.au=Seko,%20Yuya&rft.date=2013-09&rft.volume=43&rft.issue=9&rft.spage=942&rft.epage=949&rft.pages=942-949&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.12041&rft_dat=%3Cproquest_cross%3E1433271193%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1433271193&rft_id=info:pmid/23301851&rfr_iscdi=true |